EGFR Mutation Status in aNSCLC Patients
Conditions
Keywords
EGFR, aNSCLC, mutation status, diagnostic study, Russia, China, Asia
Brief summary
Interventional diagnostic, international, multicenter and non-comparative study of EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies. It will be conducted in Asia Pacific and Russia and will assess the current status of EGFR mutation testing, and the concordance of EGFR mutation status derived from tumour samples and blood based circulating free DNA.
Detailed description
A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma histologies
Interventions
GENETICEGFR mutation test
EGFR mutation being tested in tissue and blood
Sponsors
AstraZeneca
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytological confirmed locally advanced NSCLC (stage IIIA/B) not suitable for curative treatment or metastatic (stage IV) NSCLC * Newly diagnosed patients with locally advanced and/or metastatic NSCLC who are systemic treatment Naive (i.e. no chemotherapy or EGFR-TKI) or patients with recurrent disease who have previously received adjuvant chemotherapy (not including EGFR-TKI) * Provision of diagnostic cancer tissue or cytology sample upon inclusion (surgical specimen, biopsy sample, or cytology sample is acceptable) and Provision of a routine blood (plasma) sample in China, Russia, Taiwan and Korea * Patients aged 18 years and older
Exclusion criteria
* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease) * Evidence of any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study * Pregnancy or breast-feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | At Screening | The 95% Confidence intervals were calculated using Clopper Pearson method for each country. |
| Tumour EGFR Mutation by Subtype | At Screening | Frequency distribution of subjects with a positive mutation status by the mutation subtype and country. |
| Tumour EGFR Mutation Status by Histology | At Screening | Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country. |
| Overall Plasma EGFR Mutation Status | At Screening | Plasma samples were only performed in China, Taiwan, South Korea and Russia. The Confidence intervals were calculated using Clopper Pearson method for each country. |
| Plasma EGFR Mutation by Subtype | At Screening | Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequency distribution of subjects with a positive mutation status by the mutation subtype and country. |
| Plasma EGFR Mutation Status by Histology | At Screening | Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma EGFR Mutation Testing | At Screening | Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequencies of plasma EGFR mutation testing practices parameters. |
| Plasma EGFR Mutation Testing Rates | At Screening | Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation. Plasma samples were only performed in China, Taiwan, South Korea and Russia. |
| Plasma EGFR Mutation Testing Turnaround Time | At Screening | Plasma samples were only performed in China, Taiwan, South Korea and Russia. Plasma EGFR mutation testing turnaround time is the number of days from the test request to getting the test result. |
| Demographics and Disease Characteristics by Tumour EGFR Mutation Status | At Screening | Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry. |
| Time Since First Non-small-cell Lung Carcinoma (NSCLC) Diagnosis by Tumor EGFR Mutation | At Screening | Number of months since the first diagnosis of NSCLC from informed consent date. |
| Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples | At Screening | Plasma samples were only performed in China, Taiwan, South Korea and Russia. |
| Demographics and Disease Characteristics by Plasma EGFR Mutation Status | At Screening | Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry. |
| Time Since First NSCLC Diagnosis by Plasma EGFR Mutation | At Screening | Number of months since the first diagnosis of NSCLC from informed consent date. |
| Number of Organs With Metastasis by Plasma EGFR Mutation Status | At Screening | Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included. |
| First Line Treatment Choice by Asia Pacific Country | At Screening | — |
| First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | At Screening | — |
| Number of Organs With Metastasis by Tumour EGFR Mutation Status | At Screening | Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included. |
| Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | At Screening | Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants only include those who had sensitivity and specificity tests performed. |
| Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | At Screening | Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants include only those who had Positive and Negative Predictive tests performed. |
| Tumour EGFR Mutation Testing | At Screening | Frequencies of tumour EGFR mutation testing practices parameters. |
| Tumour EGFR Mutation Testing Rates | At Screening | Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation. |
| Tumour EGFR Mutation Testing Turnaround Time | At Screening | Tumour EGFR mutation testing turnaround time is the number of days from the test request to getting the test result. |
Countries
Australia, China, Indonesia, Malaysia, Russia, Singapore, South Korea, Taiwan, Thailand
Participant flow
Recruitment details
Males or females that had Stage IIIB or Stage IV adenocarcinoma of the lung and who were systemic treatment naive or patients with recurrent disease who have previously received adjuvant chemotherapy were enrolled 27 February 2013 and 25 July 2014. The study was carried out in Asiapac countries and Russia.
Pre-assignment details
A total of 3500 patients were initially enrolled, of which 118 patients were enrolled but were excluded from the study upon failure to satisfy all eligibility criteria. These patients were not included in any analysis data sets.
Participants by arm
| Arm | Count |
|---|---|
| China Subjects in China that meet I/E and population criteria. | 1,458 |
| Taiwan Subjects in Taiwan that meet I/E and population criteria | 271 |
| South Korea Subjects in South Korea that meet I/E and population criteria | 62 |
| Australia Subjects in Australia that meet I/E and population criteria | 71 |
| Thailand Subjects in Thailand that meet I/E and population criteria | 94 |
| Singapore Subjects in Singapore that meet I/E and population criteria | 102 |
| Malaysia Subjects in Malaysia that meet I/E and population criteria | 50 |
| Indonesia Subjects in Indonesia that meet I/E and population criteria | 302 |
| Russia Subjects in Russia that meet I/E and population criteria | 972 |
| Total | 3,382 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Other | 53 | 0 | 0 | 0 | 0 | 7 | 1 | 48 | 15 |
| Overall Study | Withdrawal by Subject | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Total | China | Taiwan | South Korea | Australia | Thailand | Singapore | Malaysia | Indonesia | Russia |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous Age (years) | 60.4 Years STANDARD_DEVIATION 10.73 | 59.8 Years STANDARD_DEVIATION 10.57 | 66.4 Years STANDARD_DEVIATION 12.66 | 65.9 Years STANDARD_DEVIATION 11.91 | 67.1 Years STANDARD_DEVIATION 10.02 | 61.2 Years STANDARD_DEVIATION 12.3 | 63.3 Years STANDARD_DEVIATION 10.79 | 58.7 Years STANDARD_DEVIATION 10.5 | 57.1 Years STANDARD_DEVIATION 11.46 | 59.8 Years STANDARD_DEVIATION 8.9 |
| Sex: Female, Male Female | 1142 Participants | 535 Participants | 111 Participants | 22 Participants | 36 Participants | 40 Participants | 42 Participants | 14 Participants | 97 Participants | 245 Participants |
| Sex: Female, Male Male | 2240 Participants | 923 Participants | 160 Participants | 40 Participants | 35 Participants | 54 Participants | 60 Participants | 36 Participants | 205 Participants | 727 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Overall Plasma EGFR Mutation Status
Plasma samples were only performed in China, Taiwan, South Korea and Russia. The Confidence intervals were calculated using Clopper Pearson method for each country.
Time frame: At Screening
Population: Plasma Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Overall Plasma EGFR Mutation Status | Mutation Negative | 79.3 Percentage of participants |
| China | Overall Plasma EGFR Mutation Status | Mutation Positive | 20.7 Percentage of participants |
| Taiwan | Overall Plasma EGFR Mutation Status | Mutation Positive | 26.9 Percentage of participants |
| Taiwan | Overall Plasma EGFR Mutation Status | Mutation Negative | 73.1 Percentage of participants |
| South Korea | Overall Plasma EGFR Mutation Status | Mutation Negative | 86.9 Percentage of participants |
| South Korea | Overall Plasma EGFR Mutation Status | Mutation Positive | 13.1 Percentage of participants |
| Australia | Overall Plasma EGFR Mutation Status | Mutation Negative | 90.8 Percentage of participants |
| Australia | Overall Plasma EGFR Mutation Status | Mutation Positive | 9.2 Percentage of participants |
Primary
Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status
The 95% Confidence intervals were calculated using Clopper Pearson method for each country.
Time frame: At Screening
Population: Tumour Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 59.2 Percentage of participants |
| China | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 40.8 Percentage of participants |
| Taiwan | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 52.0 Percentage of participants |
| Taiwan | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 48.0 Percentage of participants |
| South Korea | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 77.4 Percentage of participants |
| South Korea | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 22.6 Percentage of participants |
| Australia | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 70.7 Percentage of participants |
| Australia | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 29.3 Percentage of participants |
| Thailand | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 71.3 Percentage of participants |
| Thailand | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 28.7 Percentage of participants |
| Singapore | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 55.0 Percentage of participants |
| Singapore | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 45.0 Percentage of participants |
| Malaysia | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 34.7 Percentage of participants |
| Malaysia | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 65.3 Percentage of participants |
| Indonesia | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 57.5 Percentage of participants |
| Indonesia | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 42.5 Percentage of participants |
| Russia | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Negative | 88.1 Percentage of participants |
| Russia | Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status | Mutation Positive | 11.9 Percentage of participants |
Primary
Plasma EGFR Mutation by Subtype
Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequency distribution of subjects with a positive mutation status by the mutation subtype and country.
Time frame: At Screening
Population: Plasma Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Plasma EGFR Mutation by Subtype | G719X mutation only | 5 Participants |
| China | Plasma EGFR Mutation by Subtype | Exon 19 deletion only | 152 Participants |
| China | Plasma EGFR Mutation by Subtype | Exon 19 deletion + other | 0 Participants |
| China | Plasma EGFR Mutation by Subtype | T790M + other | 2 Participants |
| China | Plasma EGFR Mutation by Subtype | Exon 20 insertions only | 4 Participants |
| China | Plasma EGFR Mutation by Subtype | L858R mutation only | 122 Participants |
| China | Plasma EGFR Mutation by Subtype | S768I mutation only | 2 Participants |
| China | Plasma EGFR Mutation by Subtype | L858R mutation + Other | 0 Participants |
| China | Plasma EGFR Mutation by Subtype | L861Q mutation only | 4 Participants |
| China | Plasma EGFR Mutation by Subtype | Other | 3 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | Exon 19 deletion + other | 1 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | L861Q mutation only | 1 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | Exon 20 insertions only | 2 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | L858R mutation only | 30 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | S768I mutation only | 1 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | Other | 2 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | L858R mutation + Other | 1 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | G719X mutation only | 0 Participants |
| Taiwan | Plasma EGFR Mutation by Subtype | Exon 19 deletion only | 35 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | L858R mutation + Other | 0 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | S768I mutation only | 0 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | Other | 1 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | G719X mutation only | 0 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | T790M + other | 0 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | L858R mutation only | 6 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | L861Q mutation only | 0 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | Exon 19 deletion only | 1 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | Exon 20 insertions only | 0 Participants |
| South Korea | Plasma EGFR Mutation by Subtype | Exon 19 deletion + other | 0 Participants |
| Australia | Plasma EGFR Mutation by Subtype | Exon 20 insertions only | 1 Participants |
| Australia | Plasma EGFR Mutation by Subtype | L858R mutation + Other | 0 Participants |
| Australia | Plasma EGFR Mutation by Subtype | L858R mutation only | 25 Participants |
| Australia | Plasma EGFR Mutation by Subtype | Other | 0 Participants |
| Australia | Plasma EGFR Mutation by Subtype | S768I mutation only | 0 Participants |
| Australia | Plasma EGFR Mutation by Subtype | Exon 19 deletion only | 61 Participants |
| Australia | Plasma EGFR Mutation by Subtype | Exon 19 deletion + other | 0 Participants |
| Australia | Plasma EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Australia | Plasma EGFR Mutation by Subtype | G719X mutation only | 0 Participants |
| Australia | Plasma EGFR Mutation by Subtype | L861Q mutation only | 0 Participants |
Primary
Plasma EGFR Mutation Status by Histology
Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country
Time frame: At Screening
Population: Plasma Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Plasma EGFR Mutation Status by Histology | Mutation Negative | 74.4 Percentage of participants |
| China | Plasma EGFR Mutation Status by Histology | Mutation Positive | 25.6 Percentage of participants |
| Taiwan | Plasma EGFR Mutation Status by Histology | Mutation Positive | 6.8 Percentage of participants |
| Taiwan | Plasma EGFR Mutation Status by Histology | Mutation Negative | 93.2 Percentage of participants |
| South Korea | Plasma EGFR Mutation Status by Histology | Mutation Negative | 68.3 Percentage of participants |
| South Korea | Plasma EGFR Mutation Status by Histology | Mutation Positive | 31.7 Percentage of participants |
| Australia | Plasma EGFR Mutation Status by Histology | Mutation Negative | 90.2 Percentage of participants |
| Australia | Plasma EGFR Mutation Status by Histology | Mutation Positive | 9.8 Percentage of participants |
| Thailand | Plasma EGFR Mutation Status by Histology | Mutation Negative | 82.6 Percentage of participants |
| Thailand | Plasma EGFR Mutation Status by Histology | Mutation Positive | 17.4 Percentage of participants |
| Singapore | Plasma EGFR Mutation Status by Histology | Mutation Positive | 0.0 Percentage of participants |
| Singapore | Plasma EGFR Mutation Status by Histology | Mutation Negative | 100.0 Percentage of participants |
| Malaysia | Plasma EGFR Mutation Status by Histology | Mutation Negative | 89.3 Percentage of participants |
| Malaysia | Plasma EGFR Mutation Status by Histology | Mutation Positive | 10.7 Percentage of participants |
| Indonesia | Plasma EGFR Mutation Status by Histology | Mutation Positive | 7.1 Percentage of participants |
| Indonesia | Plasma EGFR Mutation Status by Histology | Mutation Negative | 92.9 Percentage of participants |
Primary
Tumour EGFR Mutation by Subtype
Frequency distribution of subjects with a positive mutation status by the mutation subtype and country.
Time frame: At Screening
Population: Tumour Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 11 Participants |
| China | Tumour EGFR Mutation by Subtype | L861Q mutation only | 6 Participants |
| China | Tumour EGFR Mutation by Subtype | L858R mutation + other | 1 Participants |
| China | Tumour EGFR Mutation by Subtype | G719x mutation only | 8 Participants |
| China | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 6 Participants |
| China | Tumour EGFR Mutation by Subtype | L858R mutation only | 239 Participants |
| China | Tumour EGFR Mutation by Subtype | T790M only | 0 Participants |
| China | Tumour EGFR Mutation by Subtype | Other | 6 Participants |
| China | Tumour EGFR Mutation by Subtype | S768I mutation only | 0 Participants |
| China | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 283 Participants |
| China | Tumour EGFR Mutation by Subtype | T790M + other | 2 Participants |
| China | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 3 Participants |
| China | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 2 Participants |
| China | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 0 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | L861Q mutation only | 3 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | S768I mutation only | 1 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | T790M only | 2 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 0 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 1 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | L858R mutation + other | 0 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 61 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 1 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | G719x mutation only | 1 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 2 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | Other | 1 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | L858R mutation only | 57 Participants |
| Taiwan | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | T790M only | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 1 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | G719x mutation only | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 5 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | L861Q mutation only | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | T790M + other | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | L858R mutation + other | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | Other | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | S768I mutation only | 1 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 0 Participants |
| South Korea | Tumour EGFR Mutation by Subtype | L858R mutation only | 7 Participants |
| Australia | Tumour EGFR Mutation by Subtype | G719x mutation only | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | L861Q mutation only | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | Other | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 12 Participants |
| Australia | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 1 Participants |
| Australia | Tumour EGFR Mutation by Subtype | L858R mutation only | 4 Participants |
| Australia | Tumour EGFR Mutation by Subtype | T790M only | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | L858R mutation + other | 0 Participants |
| Australia | Tumour EGFR Mutation by Subtype | S768I mutation only | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | G719x mutation only | 2 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 13 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | T790M only | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 2 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | L858R mutation only | 7 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | S768I mutation only | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | L858R mutation + other | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | L861Q mutation only | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 0 Participants |
| Thailand | Tumour EGFR Mutation by Subtype | Other | 1 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | Other | 3 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 5 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | S768I mutation only | 0 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | G719x mutation only | 0 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 0 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 3 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | L858R mutation only | 17 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | T790M only | 0 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 27 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | L861Q mutation only | 0 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 0 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 0 Participants |
| Singapore | Tumour EGFR Mutation by Subtype | L858R mutation + other | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | L858R mutation only | 8 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | S768I mutation only | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | L858R mutation + other | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 7 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | Other | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | L861Q mutation only | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | G719x mutation only | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | T790M only | 0 Participants |
| Malaysia | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 2 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | L858R mutation + other | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 43 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | L861Q mutation only | 3 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | L858R mutation only | 70 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | G719x mutation only | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | T790M only | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | Other | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | S768I mutation only | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 0 Participants |
| Indonesia | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 0 Participants |
| Russia | Tumour EGFR Mutation by Subtype | Exon 19 deletion +T790M | 0 Participants |
| Russia | Tumour EGFR Mutation by Subtype | Exon 19 deletion + other | 8 Participants |
| Russia | Tumour EGFR Mutation by Subtype | Exon 19 deletion only | 63 Participants |
| Russia | Tumour EGFR Mutation by Subtype | L858R mutation + other | 2 Participants |
| Russia | Tumour EGFR Mutation by Subtype | T790M only | 0 Participants |
| Russia | Tumour EGFR Mutation by Subtype | T790M + other | 0 Participants |
| Russia | Tumour EGFR Mutation by Subtype | L858R mutation only | 26 Participants |
| Russia | Tumour EGFR Mutation by Subtype | Exon 20 insertions only | 0 Participants |
| Russia | Tumour EGFR Mutation by Subtype | Exon 21 Other only | 6 Participants |
| Russia | Tumour EGFR Mutation by Subtype | L861Q mutation only | 2 Participants |
| Russia | Tumour EGFR Mutation by Subtype | Exon 19 Other only | 0 Participants |
| Russia | Tumour EGFR Mutation by Subtype | G719x mutation only | 0 Participants |
| Russia | Tumour EGFR Mutation by Subtype | S768I mutation only | 1 Participants |
| Russia | Tumour EGFR Mutation by Subtype | Other | 2 Participants |
Primary
Tumour EGFR Mutation Status by Histology
Only subjects who had a recorded Histological Type of Adenocarcinoma or Non-adenocarcinoma are included. Confidence intervals were calculated using Clopper Pearson method for each country.
Time frame: At Screening
Population: Tumour Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Tumour EGFR Mutation Status by Histology | Mutation Negative | 48.7 Percentage of participants |
| China | Tumour EGFR Mutation Status by Histology | Mutation Positive | 51.3 Percentage of participants |
| Taiwan | Tumour EGFR Mutation Status by Histology | Mutation Negative | 88.9 Percentage of participants |
| Taiwan | Tumour EGFR Mutation Status by Histology | Mutation Positive | 11.1 Percentage of participants |
| South Korea | Tumour EGFR Mutation Status by Histology | Mutation Negative | 42.8 Percentage of participants |
| South Korea | Tumour EGFR Mutation Status by Histology | Mutation Positive | 57.2 Percentage of participants |
| Australia | Tumour EGFR Mutation Status by Histology | Mutation Negative | 83.6 Percentage of participants |
| Australia | Tumour EGFR Mutation Status by Histology | Mutation Positive | 16.4 Percentage of participants |
| Thailand | Tumour EGFR Mutation Status by Histology | Mutation Positive | 30.4 Percentage of participants |
| Thailand | Tumour EGFR Mutation Status by Histology | Mutation Negative | 69.6 Percentage of participants |
| Singapore | Tumour EGFR Mutation Status by Histology | Mutation Positive | 0.0 Percentage of participants |
| Singapore | Tumour EGFR Mutation Status by Histology | Mutation Negative | 100.0 Percentage of participants |
| Malaysia | Tumour EGFR Mutation Status by Histology | Mutation Negative | 67.3 Percentage of participants |
| Malaysia | Tumour EGFR Mutation Status by Histology | Mutation Positive | 32.7 Percentage of participants |
| Indonesia | Tumour EGFR Mutation Status by Histology | Mutation Negative | 85.7 Percentage of participants |
| Indonesia | Tumour EGFR Mutation Status by Histology | Mutation Positive | 14.3 Percentage of participants |
| Russia | Tumour EGFR Mutation Status by Histology | Mutation Positive | 30.1 Percentage of participants |
| Russia | Tumour EGFR Mutation Status by Histology | Mutation Negative | 69.9 Percentage of participants |
| Thailand-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 15.4 Percentage of participants |
| Thailand-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 84.6 Percentage of participants |
| Singapore-Adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 56.8 Percentage of participants |
| Singapore-Adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 43.2 Percentage of participants |
| Singapore-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 33.3 Percentage of participants |
| Singapore-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 66.7 Percentage of participants |
| Malaysia-Adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 62.5 Percentage of participants |
| Malaysia-Adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 37.5 Percentage of participants |
| Malaysia-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 83.3 Percentage of participants |
| Malaysia-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 16.7 Percentage of participants |
| Indonesia-Adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 54.7 Percentage of participants |
| Indonesia-Adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 45.3 Percentage of participants |
| Indonesia-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 67.8 Percentage of participants |
| Indonesia-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 32.2 Percentage of participants |
| Russia-Adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 82.0 Percentage of participants |
| Russia-Adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 18.0 Percentage of participants |
| Russia-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Negative | 96.3 Percentage of participants |
| Russia-Non-adenocarcinoma | Tumour EGFR Mutation Status by Histology | Mutation Positive | 3.7 Percentage of participants |
Secondary
Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples
Plasma samples were only performed in China, Taiwan, South Korea and Russia.
Time frame: At Screening
Population: Tumour and Plasma Evaluable Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| China | Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples | 77.6 Percentage |
| Taiwan | Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples | 76.8 Percentage |
| South Korea | Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples | 83.6 Percentage |
| Australia | Concordance Rate of Comparison of Mutation Status Between Tumour and Plasma Samples | 85.8 Percentage |
Secondary
Demographics and Disease Characteristics by Plasma EGFR Mutation Status
Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry.
Time frame: At Screening
Population: Plasma Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Gender: Male | 228 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 7 | 3 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Gender: Female | 234 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 3 | 67 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Region: Asia Pacific | 375 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Histology: Adenocarcinoma | 397 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Region: Russia | 87 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 5 | 12 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Age: <=65 | 337 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Histology: Non-adenocarcinoma | 60 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Age: >65 | 125 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 2 | 120 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | WHO Performance Status: 0-1 | 400 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Smoking Status: Never-Smoker | 298 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | WHO Performance Status: 2 | 43 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 6 | 2 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Current Disease Status: IIIA | 23 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Smoking Status: Ever-Smoker | 164 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Current Disease Status: IIIB | 32 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 4 | 37 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Current Disease Status: IV | 407 Participants |
| China | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 1 | 167 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Current Disease Status: IV | 1597 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 1 | 956 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 2 | 420 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 3 | 155 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 4 | 57 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 5 | 17 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 6 | 2 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Number of Organs with Metastasis = 7 | 0 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Histology: Adenocarcinoma | 1417 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Histology: Non-adenocarcinoma | 794 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Smoking Status: Never-Smoker | 835 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Smoking Status: Ever-Smoker | 1397 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Gender: Male | 1575 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Gender: Female | 657 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Region: Asia Pacific | 1378 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Region: Russia | 854 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Age: <=65 | 1454 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Age: >65 | 778 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | WHO Performance Status: 0-1 | 1956 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | WHO Performance Status: 2 | 237 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Current Disease Status: IIIA | 257 Participants |
| Taiwan | Demographics and Disease Characteristics by Plasma EGFR Mutation Status | Current Disease Status: IIIB | 378 Participants |
p-value: 0.0009Regression Stepwise
p-value: 0.0009Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0002Regression Stepwise
p-value: 0.0002Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0001Regression Stepwise
Secondary
Demographics and Disease Characteristics by Tumour EGFR Mutation Status
Correlation of demographic and disease characteristics are summarized by EGFR mutation status with results from a multivariate logistic regression using stepwise forward selection with a 10% significance level for model entry.
Time frame: At Screening
Population: Tumour Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | World Health Organization Performance Status: 2 | 128 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Region: Asia Pacific | 941 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Current Disease Status: IIIA | 42 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Smoking Status: Never-Smoker | 705 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Current Disease Status: IIIB | 86 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Region: Russia | 110 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Current Disease Status: IV | 923 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Gender: Male | 480 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 1 | 458 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Age: <=65 | 695 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 2 | 266 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Histology: Non-adenocarcinoma | 89 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 3 | 127 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | >65 | 356 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 4 | 53 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Gender: Female | 571 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 5 | 16 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | World Health Organization Performance Status: 0-1 | 866 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 6 | 2 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Smoking Status: Ever-Smoker | 346 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 7 | 3 Participants |
| China | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Histology: Adenocarcinoma | 952 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 7 | 1 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Histology: Adenocarcinoma | 1297 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Histology: Non-adenocarcinoma | 838 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Smoking Status: Never-Smoker | 647 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Smoking Status: Ever-Smoker | 1517 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Gender: Male | 1647 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Gender: Female | 517 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Region: Asia Pacific | 1350 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Region: Russia | 814 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Age: <=65 | 1447 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | >65 | 717 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | World Health Organization Performance Status: 0-1 | 1808 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | World Health Organization Performance Status: 2 | 276 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Current Disease Status: IIIA | 266 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Current Disease Status: IIIB | 371 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Current Disease Status: IV | 1527 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 1 | 901 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 2 | 408 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 3 | 149 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 4 | 61 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 5 | 15 Participants |
| Taiwan | Demographics and Disease Characteristics by Tumour EGFR Mutation Status | Number of Organs with Metastasis = 6 | 2 Participants |
p-value: 0.0001Regression stepwise
p-value: 0.0001Regression stepwise
p-value: 0.0075Regression Stepwise
p-value: 0.0075Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0001Regression Stepwise
p-value: 0.0909Regression Stepwise
p-value: 0.0909Regression Stepwise
Secondary
First Line Treatment Choice by Asia Pacific Country
Time frame: At Screening
Population: Tumour Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 0 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 133 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Vincristine | 0 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 77 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 240 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 1151 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 5 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 7 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 62 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 332 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 1329 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 33 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 17 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 1383 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 424 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 137 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Icotinib | 55 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Other: No | 1358 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 8 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 284 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Etoposide | 12 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 41 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 21 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 273 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 142 Participants |
| China | First Line Treatment Choice by Asia Pacific Country | Afatinib | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Afatinib | 4 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 14 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Etoposide | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 245 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 65 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 6 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 53 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 265 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Vincristine | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 25 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 18 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Other: No | 271 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 26 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 11 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 5 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 2 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 218 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 12 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Icotinib | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 22 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 46 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 15 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 2 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 9 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Icotinib | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 5 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 6 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 61 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 10 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 18 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 1 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 1 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 9 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Other: No | 62 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Etoposide | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 2 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 14 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Vincristine | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Afatinib | 1 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 1 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 44 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 48 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 2 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 2 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 13 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 1 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 26 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Afatinib | 3 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 1 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Other: No | 56 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 3 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 45 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 5 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Etoposide | 2 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 44 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 3 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 25 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Icotinib | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 14 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 4 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Vincristine | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 58 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 1 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 65 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 2 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 9 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 3 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 1 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Icotinib | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 46 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 7 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Other: No | 87 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 87 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Afatinib | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 52 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Vincristine | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 22 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 1 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Etoposide | 3 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 84 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 2 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Etoposide | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 1 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 5 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 16 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 11 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 87 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 25 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Other: No | 100 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 99 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Icotinib | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Afatinib | 10 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 89 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 3 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 21 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 1 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 9 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Vincristine | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 4 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 13 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 23 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Icotinib | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 29 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 20 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Afatinib | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 10 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 12 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Etoposide | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 4 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 22 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 1 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Vincristine | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 2 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 1 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 48 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 17 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 32 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country | Other: No | 49 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 100 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Vincristine | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 273 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 18 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Icotinib | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 1 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 99 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 7 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 73 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Etoposide | 11 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 266 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 174 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Afatinib | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Other: No | 273 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Surgery: Yes | 12 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Vinorelbine | 4 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: No | 852 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Vincristine | 3 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Docetaxel | 19 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Pemetrexed | 28 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Other Chemotherapy | 44 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Bevacizumab | 1 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Afatinib | 13 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Surgery: No | 912 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Paclitaxel | 166 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Cisplatin | 301 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Icotinib | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: No | 283 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Gemcitabine | 46 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Cetuximab | 1 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Crizotinib | 3 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Investigational agent | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Radiotherapy: Yes | 72 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Gefitinib | 33 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Other: Yes | 8 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Etoposide | 244 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Other: No | 916 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Erlotinib | 4 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Carboplatin | 235 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country | Systemic Anticancer Treatment: Yes | 641 Participants |
Secondary
First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status
Time frame: At Screening
Population: Tumour Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 139 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 553 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 37 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 565 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 123 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 17 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 68 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 2 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 127 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 19 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 1 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 546 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 499 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 61 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 96 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 14 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 1 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 52 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 50 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 14 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 21 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 15 Participants |
| China | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 5 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 27 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 4 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 783 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 652 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 177 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 193 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 96 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 172 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 7 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 11 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 58 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 805 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 41 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 301 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 818 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 6 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 19 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 10 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 223 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 90 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 4 Participants |
| Taiwan | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 2 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 3 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 130 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 128 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 8 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 122 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 2 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 125 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 5 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 4 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 1 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 3 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 2 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 1 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 65 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 2 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| South Korea | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 43 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 3 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 19 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 13 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 4 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 96 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 117 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 1 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 140 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 9 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 141 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 15 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 45 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 10 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 25 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 24 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 2 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Australia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 12 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 2 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 1 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 1 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 2 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 6 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 1 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 2 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 14 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 3 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 11 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Thailand | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 14 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 32 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 37 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 9 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 15 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 48 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 47 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 1 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 5 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 1 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 8 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 1 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 16 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 9 Participants |
| Singapore | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 11 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 1 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 1 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 13 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 3 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 14 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 3 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 5 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 15 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 3 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 17 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 4 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 1 Participants |
| Malaysia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 2 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 2 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 3 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 32 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 2 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 30 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 24 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 11 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 25 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 9 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 41 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 4 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 1 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 41 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 1 Participants |
| Indonesia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 25 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 2 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 23 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 1 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 6 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 13 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 16 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 25 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 2 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 19 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Russia | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 3 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 6 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 1 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 46 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 62 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 3 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 33 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 16 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 2 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 5 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 62 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 36 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 1 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 61 Participants |
| Thailand-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 1 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 3 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 6 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 21 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 1 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 54 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 5 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 10 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 55 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 2 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 1 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 1 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 16 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 49 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 55 Participants |
| Singapore-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 40 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 4 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 22 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 3 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 8 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 45 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 2 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 5 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 12 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 1 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 2 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 18 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 33 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Singapore-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 44 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 3 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 4 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 3 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 6 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 7 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 17 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 17 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 6 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 11 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 10 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Malaysia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 1 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 1 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 2 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 9 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 21 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 7 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 19 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 11 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 16 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 31 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 32 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 13 Participants |
| Malaysia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 36 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 4 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 116 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 16 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 1 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 2 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 80 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 73 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 8 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 114 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 3 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Indonesia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 157 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 5 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 94 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 157 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 94 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 152 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 8 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 0 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 14 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 63 Participants |
| Indonesia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 2 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 1 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 24 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 15 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 0 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 0 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 2 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 3 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 103 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 28 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 18 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 109 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 18 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 13 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 3 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 0 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 1 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 108 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 0 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 3 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 24 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 7 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 86 Participants |
| Russia-Adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 0 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vinorelbine | 4 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gefitinib | 9 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cetuximab | 1 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? No | 259 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Crizotinib | 3 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: Yes | 7 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: No | 804 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Vincristine | 3 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Docetaxel | 16 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Icotinib | 0 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Surgery: Yes | 10 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Afatinib | 0 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other: No | 807 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Paclitaxel | 148 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Systemic Anticancer Treatment? Yes | 555 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: No | 749 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Other Chemotherapy | 41 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Cisplatin | 286 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Etoposide | 226 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Gemcitabine | 44 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Investigational Agent | 0 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Pemetrexed | 27 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Bevacizumab | 1 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Radiotherapy: Yes | 65 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Carboplatin | 207 Participants |
| Russia-Non-adenocarcinoma | First Line Treatment Choice by Asia Pacific Country by Tumour EGFR Mutation Status | Erlotinib | 1 Participants |
Secondary
Number of Organs With Metastasis by Plasma EGFR Mutation Status
Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included.
Time frame: At Screening
Population: Plasma Evaluable Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| China | Number of Organs With Metastasis by Plasma EGFR Mutation Status | 2.1 Number | Standard Deviation 1.21 |
| Taiwan | Number of Organs With Metastasis by Plasma EGFR Mutation Status | 1.6 Number | Standard Deviation 0.89 |
Secondary
Number of Organs With Metastasis by Tumour EGFR Mutation Status
Summary of number of organs with metastasis. Only participants with at least 1 organ with metastasis are included.
Time frame: At Screening
Population: Tumour Evaluable Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| China | Number of Organs With Metastasis by Tumour EGFR Mutation Status | 1.8 Number | Standard Deviation 1.05 |
| Taiwan | Number of Organs With Metastasis by Tumour EGFR Mutation Status | 1.6 Number | Standard Deviation 0.91 |
Secondary
Plasma EGFR Mutation Testing
Plasma samples were only performed in China, Taiwan, South Korea and Russia. Frequencies of plasma EGFR mutation testing practices parameters.
Time frame: At Screening
Population: Enrolled Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Plasma EGFR Mutation Testing | Mutation Test Not performed | 37 Participants |
| China | Plasma EGFR Mutation Testing | Plasma Sample | 1421 Participants |
| Taiwan | Plasma EGFR Mutation Testing | Mutation Test Not performed | 0 Participants |
| Taiwan | Plasma EGFR Mutation Testing | Plasma Sample | 271 Participants |
| South Korea | Plasma EGFR Mutation Testing | Plasma Sample | 62 Participants |
| South Korea | Plasma EGFR Mutation Testing | Mutation Test Not performed | 0 Participants |
| Australia | Plasma EGFR Mutation Testing | Plasma Sample | 950 Participants |
| Australia | Plasma EGFR Mutation Testing | Mutation Test Not performed | 22 Participants |
Secondary
Plasma EGFR Mutation Testing Rates
Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation. Plasma samples were only performed in China, Taiwan, South Korea and Russia.
Time frame: At Screening
Population: Enrolled Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Plasma EGFR Mutation Testing Rates | Testing Success Rate | 100.0 Percentage of Participants |
| China | Plasma EGFR Mutation Testing Rates | Mutation Detection Rate | 20.7 Percentage of Participants |
| Taiwan | Plasma EGFR Mutation Testing Rates | Mutation Detection Rate | 26.9 Percentage of Participants |
| Taiwan | Plasma EGFR Mutation Testing Rates | Testing Success Rate | 100.0 Percentage of Participants |
| South Korea | Plasma EGFR Mutation Testing Rates | Testing Success Rate | 98.4 Percentage of Participants |
| South Korea | Plasma EGFR Mutation Testing Rates | Mutation Detection Rate | 12.9 Percentage of Participants |
| Australia | Plasma EGFR Mutation Testing Rates | Testing Success Rate | 99.1 Percentage of Participants |
| Australia | Plasma EGFR Mutation Testing Rates | Mutation Detection Rate | 9.2 Percentage of Participants |
Secondary
Plasma EGFR Mutation Testing Turnaround Time
Plasma samples were only performed in China, Taiwan, South Korea and Russia. Plasma EGFR mutation testing turnaround time is the number of days from the test request to getting the test result.
Time frame: At Screening
Population: Enrolled Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| China | Plasma EGFR Mutation Testing Turnaround Time | 39.8 Time (Days) | Standard Deviation 44.24 |
| Taiwan | Plasma EGFR Mutation Testing Turnaround Time | 26.7 Time (Days) | Standard Deviation 12.62 |
| South Korea | Plasma EGFR Mutation Testing Turnaround Time | 18.1 Time (Days) | Standard Deviation 13.72 |
| Australia | Plasma EGFR Mutation Testing Turnaround Time | 90.1 Time (Days) | Standard Deviation 105.69 |
Secondary
Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples
Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants include only those who had Positive and Negative Predictive tests performed.
Time frame: At Screening
Population: Tumour and Plasma Evaluable Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| China | Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | 92.1 Percentage |
| Taiwan | Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | 73.6 Percentage |
| South Korea | Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | 95.9 Percentage |
| Australia | Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | 69.7 Percentage |
| Thailand | Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | 75.0 Percentage |
| Singapore | Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | 84.9 Percentage |
| Malaysia | Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | 39.3 Percentage |
| Indonesia | Predictive Values of Comparison of Mutation Status Between Tumour and Plasma Samples | 90.6 Percentage |
Secondary
Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples
Plasma samples were only performed in China, Taiwan, South Korea, and Russia. Participants only include those who had sensitivity and specificity tests performed.
Time frame: At Screening
Population: Tumour and Plasma Evaluable Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| China | Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | 48.7 Percentage |
| Taiwan | Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | 97.1 Percentage |
| South Korea | Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | 53.8 Percentage |
| Australia | Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | 97.9 Percentage |
| Thailand | Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | 42.9 Percentage |
| Singapore | Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | 95.7 Percentage |
| Malaysia | Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | 30.3 Percentage |
| Indonesia | Sensitivity and Specificity of Comparison of Mutation Status Between Tumour and Plasma Samples | 93.5 Percentage |
Secondary
Time Since First Non-small-cell Lung Carcinoma (NSCLC) Diagnosis by Tumor EGFR Mutation
Number of months since the first diagnosis of NSCLC from informed consent date.
Time frame: At Screening
Population: Tumour Evaluable Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| China | Time Since First Non-small-cell Lung Carcinoma (NSCLC) Diagnosis by Tumor EGFR Mutation | 2.6 Months | Standard Deviation 8.93 |
| Taiwan | Time Since First Non-small-cell Lung Carcinoma (NSCLC) Diagnosis by Tumor EGFR Mutation | 2.6 Months | Standard Deviation 9.79 |
Secondary
Time Since First NSCLC Diagnosis by Plasma EGFR Mutation
Number of months since the first diagnosis of NSCLC from informed consent date.
Time frame: At Screening
Population: Plasma Evaluable Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| China | Time Since First NSCLC Diagnosis by Plasma EGFR Mutation | 2.2 Months | Standard Deviation 7.99 |
| Taiwan | Time Since First NSCLC Diagnosis by Plasma EGFR Mutation | 3.0 Months | Standard Deviation 11.09 |
Secondary
Tumour EGFR Mutation Testing
Frequencies of tumour EGFR mutation testing practices parameters.
Time frame: At Screening
Population: Enrolled Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Tumour EGFR Mutation Testing | Tumour Sample | 1394 Participants |
| China | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 64 Participants |
| Taiwan | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 0 Participants |
| Taiwan | Tumour EGFR Mutation Testing | Tumour Sample | 271 Participants |
| South Korea | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 0 Participants |
| South Korea | Tumour EGFR Mutation Testing | Tumour Sample | 62 Participants |
| Australia | Tumour EGFR Mutation Testing | Tumour Sample | 60 Participants |
| Australia | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 11 Participants |
| Thailand | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 2 Participants |
| Thailand | Tumour EGFR Mutation Testing | Tumour Sample | 92 Participants |
| Singapore | Tumour EGFR Mutation Testing | Tumour Sample | 101 Participants |
| Singapore | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 1 Participants |
| Malaysia | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 1 Participants |
| Malaysia | Tumour EGFR Mutation Testing | Tumour Sample | 49 Participants |
| Indonesia | Tumour EGFR Mutation Testing | Tumour Sample | 273 Participants |
| Indonesia | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 29 Participants |
| Russia | Tumour EGFR Mutation Testing | Mutation Test Not Performed | 36 Participants |
| Russia | Tumour EGFR Mutation Testing | Tumour Sample | 936 Participants |
Secondary
Tumour EGFR Mutation Testing Rates
Testing Success rate is the percentage of subjects with a non-missing test result. Mutation Detection Rate is the percentage of subjects with successful test that detects a mutation.
Time frame: At Screening
Population: Enrolled Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| China | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 99.8 Percentage of Participants |
| China | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 40.7 Percentage of Participants |
| Taiwan | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 100.0 Percentage of Participants |
| Taiwan | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 48.0 Percentage of Participants |
| South Korea | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 100.0 Percentage of Participants |
| South Korea | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 24.2 Percentage of Participants |
| Australia | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 96.7 Percentage of Participants |
| Australia | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 28.3 Percentage of Participants |
| Thailand | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 94.6 Percentage of Participants |
| Thailand | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 27.2 Percentage of Participants |
| Singapore | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 54.5 Percentage of Participants |
| Singapore | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 99.0 Percentage of Participants |
| Malaysia | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 34.7 Percentage of Participants |
| Malaysia | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 100.0 Percentage of Participants |
| Indonesia | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 100.0 Percentage of Participants |
| Indonesia | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 42.5 Percentage of Participants |
| Russia | Tumour EGFR Mutation Testing Rates | Testing Success Rate | 98.7 Percentage of Participants |
| Russia | Tumour EGFR Mutation Testing Rates | Mutation Detection Rate | 12.7 Percentage of Participants |
Secondary
Tumour EGFR Mutation Testing Turnaround Time
Tumour EGFR mutation testing turnaround time is the number of days from the test request to getting the test result.
Time frame: At Screening
Population: Enrolled Population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| China | Tumour EGFR Mutation Testing Turnaround Time | 6.2 Time (Days) | Standard Deviation 5.34 |
| Taiwan | Tumour EGFR Mutation Testing Turnaround Time | 7.4 Time (Days) | Standard Deviation 12.29 |
| South Korea | Tumour EGFR Mutation Testing Turnaround Time | 11.7 Time (Days) | Standard Deviation 12.7 |
| Australia | Tumour EGFR Mutation Testing Turnaround Time | 12.9 Time (Days) | Standard Deviation 8.19 |
| Thailand | Tumour EGFR Mutation Testing Turnaround Time | 70.8 Time (Days) | Standard Deviation 43.85 |
| Singapore | Tumour EGFR Mutation Testing Turnaround Time | 8.4 Time (Days) | Standard Deviation 4.9 |
| Malaysia | Tumour EGFR Mutation Testing Turnaround Time | 8.6 Time (Days) | Standard Deviation 3.55 |
| Indonesia | Tumour EGFR Mutation Testing Turnaround Time | 6.5 Time (Days) | Standard Deviation 2.33 |
| Russia | Tumour EGFR Mutation Testing Turnaround Time | 14.3 Time (Days) | Standard Deviation 26.84 |